Emergen Research latest document, titled ‘Global Chronic Rhinosinusitis Market - Forecast to 2027,’ is one of the most sought-after market reports involving an in-depth analysis of the global Chronic Rhinosinusitis market. The report’s authors have offered necessary details on the latest Chronic Rhinosinusitis market trends and the crucial parameters impacting both short-term and long-term market growth. Its panoramic view of the Chronic Rhinosinusitis industry entails useful insights into the estimated Chronic Rhinosinusitis market size, revenue share, and sales distribution network such helpful market insights are bound to help readers outline this industry’s key outcomes in the near future
Additionally, increase in implementation of minimally invasive surgical procedures, widespread awareness concerning the symptoms of the target disease across regions and technological progressions among other favorable scenarios are likely to augment the growth of industry during the period of 2020-2027. However, low preference towards sinus surgical undertakings, post-surgery risks of sinus treatment and high cost of treatment may hinder the growth of chronic rhinosinusitis market in the forecast period.
Key market companies studied and profiled for this research include AstraZeneca, Bayer AG, Ivax Pharmaceuticals, Pfizer, Novartis Pharmaceuticals Corporation, Sanofi, Sunovion Pharmaceuticals, Cipla, Smith Nephew, Medtronic, SinuSys Corporation, Olympus Corporation and Acclarent among other companies
Get a Free sample of the report : https://www.emergenresearch.com/request-sample/74
The report is updated with the latest economic scenario and market scope with regard to the ongoing COVID-19 pandemic. The report covers growth prospects as well as current and futuristic revenue estimations in a post COVID scenario. The report also covers changing trends and market dynamics due to the pandemic and provides an accurate impact analysis of the crisis on the overall market.
Chronic rhinosinusitis is primarily characterized by nasel blockage, inflammation of the sinus and nasel linings, facial pain along with rhinorrhea and loss of sense of smell. Effective treatment includes improvement in sinus outflow, enhancement of mucociliary clearance and elimination of inflammation and local infection among other associated treatments.
Some Key Highlights from the Report
Xolair (Omalizumab) manufactured by Novartis, was approved in August 2020, by European Commission (EC). The product development is attributed to treat severe chronic rhinosinusitis with nasal polyps
Due to considerable employability of antibiotics and their effectiveness in efficiently treating chronic rhinosinusitis, antibiotics product segment held largest market share of 41.6% in 2019 and is likely to dominate the industry during 2019-2027
Immune deficiency disease segment in the disease outlook registered highest CAGR of 7.1% in 2019 whereas, anatomical differences disease segment accounted for largest market share of approximately 37.5% owing to increase in prevalence of target disease across the globe
Regeneron Pharmaceuticals and Sanofi’s Dupixent (Dupilumab) was approved in June 2019, by US Food and Drug Administration (FDA). This drug is customized for adults with incompetently controlled chronic rhinosinusitis along with nasal polyposis
Owing to favourable reimbursement policies, high prevalence of target disease and technological advancements among other encouraging scenarios North America accounted for largest market revenue with significant market share of 37.2% in 2019
Key Questions Answered in the Report:
What is the growth rate of the Chronic Rhinosinusitis market? What is the anticipated market valuation of Chronic Rhinosinusitis industry by 2027?
What are the key growth driving and restraining factors of the Chronic Rhinosinusitis market?
Who are the prominent players operating in the market? What are the key strategies adopted by these companies?
What are the key opportunities and growth prospects of the Chronic Rhinosinusitis industry over the forecast period?
Which region is expected to show significant growth in the coming years?
Request customization of the report: https://www.emergenresearch.com/request-for-customization/74
Market Taxonomy:
Chapter 1: Methodology Scope
Definition and forecast parameters
Methodology and forecast parameters
Data Sources
Chapter 2:
Executive Summary
Business trends
Regional trends
Product trends
End-use trends
Chapter 3:
Industry Insights
Industry segmentation
Industry landscape
Vendor matrix
Technological and innovation landscape
Chapter 4:
Regional Landscape
Chapter 5:
Company Profile
Business Overview
Financial Data
Product Landscape
Strategic Outlook
Emergen Research have segmented Chronic Rhinosinusitis Market on the basis of product, disease type, distribution channel and region:
Product Outlook (Revenue in Million USD; 2017–2027)
Steroids
Topical Nasal Steroid
Systemic Steroids
Nasal Irrigation
Hypertonic and Isotonic Saline
Steroid Nasal Irrigation
Topical Antibiotic Therapy
Surgical Based
Ethmoidectomy
Endoscopic Intranasal Intervention
Others
Antibiotics
Amoxicillin-Clavulanate
Clindamycin
Sulfamethoxazole
Levofloxacin
Macrolide Therapy
Antifungal Therapy
Disease Outlook (Revenue in Million USD; 2017–2027)
Anatomical Differences
Nasal Tumors
Mucosal Edema
Non-Allergic Rhinitis
Immune Deficiency
Other
Distribution Channel (Revenue in Million USD; 2017–2027)
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Other
Global Chronic Rhinosinusitis Market Geographical Landscape - Synopsis:
The report closely studies the growth trajectory of the global Chronic Rhinosinusitis market. It brings to light the global dominance of the leading regional segments, including North America, Asia Pacific, Europe, Latin America, and the Middle East Africa.
The study elaborates on the crucial information pertaining to the regional market share. It simultaneously focuses on the significant details about the growth patterns of each regional market.
Moreover, the report encases an exhaustive geographical study of the market, emphasizing the business growth prospects and market barriers for each of the key market regions.
Read More: https://www.emergenresearch.com/industry-report/chronic-rhinosinusitis-market
Related reports:
tissue engineering market
medical holographic imaging market
human microbiome therapeutics market
water-soluble drugs market
ambulatory device market
https://www.google.dz/url?q=https://www.emergenresearch.com/industry-report/ambulatory-device-market
mobile c-arms market
https://www.google.dz/url?q=https://www.emergenresearch.com/industry-report/mobile-c-arms-market
anti-aging devices market
About Us:
At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Facebook | LinkdIn | Twitter | Blogs
